Last reviewed · How we verify
Measles-Mumps-Rubella
The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens.
The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens. Used for Prevention of measles, Prevention of mumps, Prevention of rubella.
At a glance
| Generic name | Measles-Mumps-Rubella |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Live attenuated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains live weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease. This triggers both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and rapidly neutralize wild-type viruses upon future exposure. Protection is typically long-lasting and often lifelong.
Approved indications
- Prevention of measles
- Prevention of mumps
- Prevention of rubella
Common side effects
- Fever
- Rash
- Local injection site reactions (pain, erythema, swelling)
- Parotitis
- Arthralgia/arthritis
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age (PHASE3)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles-Mumps-Rubella CI brief — competitive landscape report
- Measles-Mumps-Rubella updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI